mRNA

BIOLOGICAL3 trials

Sponsors

University Hospital Tuebingen, Shanghai Siponuoyin Biotechnology Co Ltd

Conditions

Duchenne Muscular Dystrophy (DMD)Malignant MelanomaRecurrent Prostate Cancer

Early Phase 1

Safety and Dystrophin Expression of SPOT-mRNA03 in Duchenne Muscular Dystrophy (DMD) Patients

RecruitingNCT07188012

Shanghai Siponuoyin Biotechnology Co LtdDuchenne Muscular Dystrophy (DMD)

Start: 2025-08-06End: 2026-12-31Target: 6Updated: 2025-09-23

Phase 1

Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients

CompletedNCT00204607

University Hospital TuebingenMalignant Melanoma

Start: 2004-07-31End: 2007-01-31Target: 20Updated: 2007-04-19

Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy

University Hospital TuebingenRecurrent Prostate Cancer

Start: 2004-04-30End: 2017-10-31Updated: 2017-08-17